At CVS Health, we are committed to providing high-quality and cost-effective medications to our patients. One of the ways we achieve this is through the use of biosimilar drugs. These drugs are essential for patients who require treatment for chronic and severe conditions, as they can be used to treat a wide range of conditions, from certain types of cancer to diabetes.
In a recent report written by Dr. Sree Chaguturu, Executive Vice President and Chief Medical Officer at CVS Health, the benefits of biosimilar drugs in making treatments more affordable were highlighted. The report also discussed the role of Cordavis™, a CVS Health subsidiary that focuses on producing high-quality biosimilars, in improving patient access to these life-changing treatments and driving innovation in healthcare.
The use of biosimilar drugs represents a significant opportunity for managing drug costs within the healthcare system. By using these medications instead of branded drugs, patients can save money without compromising on the quality of their treatment. Additionally, biosimilars can be produced at a lower cost than branded drugs, making them more accessible to patients who may not have been able to afford them otherwise.
To learn more about the impact of biosimilar drugs and how they are making healthcare more accessible, you can read the full report (PDF) authored by Dr. Sree Chaguturu.